Current position

Joel Greenblatt’s Ionis Pharmaceuticals Inc (IONS) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Gotham Asset ManagementVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ4 2016Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares357.46KHighest verified quarter-end share count
Quarters reported28Verified quarters with shares above zero
What happened?

Gotham Asset Management first reported Ionis Pharmaceuticals Inc in Q4 2016. After an earlier exit, the position later appeared again in a verified filing. The reported position was increased and reduced across later filings. Gotham Asset Management currently reports 121.25K shares. The latest verified filing showed: Bought 22.5% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 22.5% more+22.28K shares · 121.25K shares reported after the change
Filing context

Quarter-end price $79.29 · Estimated holding basis $70.61

Q1 2026
Bought 129.0% more+55.76K shares · 98.97K shares reported after the change
Filing context

Quarter-end price $75.09 · Estimated holding basis $68.66

Q4 2025
Bought 34.4% more+11.06K shares · 43.21K shares reported after the change
Filing context

Quarter-end price $79.11 · Estimated holding basis $60.36

Q3 2025
Bought 125.2% more+17.87K shares · 32.15K shares reported after the change
Filing context

Quarter-end price $65.42 · Estimated holding basis $53.91

Q2 2025
New position+14.28K shares · 14.28K shares reported
Filing context

Quarter-end price $39.51 · Estimated holding basis $39.51

Q1 2025
Sold the entire position−6.26K shares · No shares reported at quarter-end

1 unchanged quarter is collapsed by default.

Portfolio importance

How important is Ionis Pharmaceuticals Inc in Gotham Asset Management’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.0%Q2 2026
Current rank#802of 1791 reported positions
Peak portfolio weight0.3%Q2 2017
Best historical rank#124Q2 2017
At peak importanceQ2 2017
IONS
0.3%
Largest holding
1.0%
Cross-investor discovery

Who else owns Ionis Pharmaceuticals Inc?

Also reported by 1 other tracked investor in their latest verified filings.

Cathie WoodARK Investment Management
IONS0.2% of reported portfolio
Explore Ionis Pharmaceuticals Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$44.842026-09-16

Market context only; not an investor transaction price.

Latest filing quarter-end price$79.29Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$70.61Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Gotham Asset Management, LLC’s Form 13F disclosures—not Joel Greenblatt’s personal brokerage account. The filing is firm-level rather than a personal stock list. Form 13F reports quarter-end U.S.-listed positions and certain options, but it does not reveal exact trade dates, execution prices, short positions or the purpose of an option position.